53484-18-7

Basic information

• Product Name: 1H-Benzimidazole-6-carboxylicacid,1-methyl-(9CI)
• Synonyms: 1H-Benzimidazole-6-carboxylicacid,1-methyl-(9CI);1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID;1-Methyl-1H-1,3-benzodiazole-6-carboxylic acid;3-Methyl-3H-benzo[d]iMidazole-5-carboxylic acid;1-Methyl-6-benziMidazole carboxylic acid;1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid;1-Methylbenzimidazole-6-carboxylic acid;3-Methyl-3H-benzoimidazole-5-carboxylic acid
• CAS NO: 53484-18-7
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.18
• Product Categories: BENZIMIDAZOLE
• Mol File: 53484-18-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 411.1 °C at 760 mmHg
• Flash Point: 202.4 °C
• Appearance: /
• Density: 1.35 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Benzimidazole-6-carboxylicacid,1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-6-carboxylicacid,1-methyl-(9CI)(53484-18-7)
• EPA Substance Registry System: 1H-Benzimidazole-6-carboxylicacid,1-methyl-(9CI)(53484-18-7)

Safety Data

• Hazardous Substances Data: 53484-18-7(Hazardous Substances Data)

Usage

Uses

1-Methylbenzimidazole-6-carboxylic Acid is used as a reagent in the synthesis of aminopyridine-derived amides as nicotinamide phosphoribosyltransferase inhibitors. Also used as a reagent in the synthesis of nitazoxanide-N-methylbenzimidazole hybrids which exhibit antiprotozoal activity.

Upstream product

• 263409-77-4 2-(4,6-difluoro-1H-benzoimidazol-2-ylmethyl)-3-methyl-3H-benzoimidazole-5-carboxylic acid 
• 67-56-1 methanol 
• 131020-50-3 methyl 1-methyl-1H-benzo[d]imidazole-6-carboxylate 
• 616224-38-5 methyl 4-amino-3-(methylamino)benzoate 
• 251643-13-7 methyl 3-(methylamino)-4-nitrobenzoate 
• 10394-40-8 1,6-dimethylbenzimidazole 

Relevant articles and documents

Synthesis and antiprotozoal activity of nitazoxanide-N-methylbenzimidazole hybrids

A series of a novel hybrid compounds between nitazoxanide and N-methylbenzimidazole were synthesized starting from the corresponding N-methyl-2-nitroanilines. The new hybrid compounds (1-13) were evaluated in vitro against Giardia intestinalis, Entamoeba

Neutrophil inhibitors to reduce inflammatory response

The invention provides novel compounds selected from the group consisting of: The compounds of the present invention are useful for the treatment and prevention of a variety of diseases and conditions associated with undesirable or abnormal inflammatory responses, such as ischemia-reperfusion injury. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment or prevention for the above disorders using theses compounds or the compositions containing them.